Filing Flows › Cytosorbents (CTSO) › Q4 2024
Cytosorbents (CTSO) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 31, 2025
Cytosorbents (CTSO) reported revenue of $6.5M for the fourth quarter 2024 (Q4 2024), -25% from a year earlier and -31% from the quarter before. Operating margin was -52.0%, net loss $7.6M (116.0% of revenue).
Cytosorbents, Q4 2024: revenue $6.5M (-25% year over year), operating margin -52.0%, net loss $7.6M, operating cash flow −$2.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $6.5M | -31% | -25% |
| Operating profit | −$3.4M | — | — |
| Net earnings | −$7.6M | — | — |
| Operating cash flow | −$2.3M | — | — |
What changed
Revenue was $6.5M in Q4 2024, down 25% year over year and down 31% from the previous quarter.
Gross margin was 95.9%, up 34.6 points from a year earlier. Operating costs exceeded revenue by $3.4M, an operating margin of -52.0%. Operating expenses fell 34% while revenue fell 25%. The quarter ended with a net loss of $7.6M, wider than the previous quarter's $2.3M loss. Net interest and other expense of $5.9M was the main reason.
Operating cash flow was −$2.3M. Non-cash charges added back $389K of depreciation and amortization and $1.4M of share-based compensation. Working capital and other items added $3.4M. Capital expenditures of $69K exceeded it, leaving free cash flow of −$2.4M.
Questions
What was Cytosorbents' revenue in the fourth quarter 2024?
Cytosorbents (CTSO) reported revenue of $6.5M for the fourth quarter 2024 (Q4 2024), -25% from a year earlier and -31% from the quarter before.
Was Cytosorbents profitable in the fourth quarter 2024?
Operating loss was $3.4M (-52.0% of revenue) and net loss $7.6M.
Source: Cytosorbents 10-K on SEC EDGAR.